Abstract
People with diabetes represent a population at greater risk of infection
and complications from Sars-Cov-2 (COVID-19), Diabetes represents one of
the most important comorbidities related to the severity of viral
infection causing an increased risk of serious complications such as
severe acute respiratory syndrome and multi-organ dysfunction associated
with a hyperinflammatory state. Glycemic normalization in patients with
diabetes must be managed in the best possible way even during COVID-19
infection to avoid serious complications. However, for some antidiabetic
agents such as DPP-4 inhibitors (gliptins) there is evidence of efficacy
against COVID-19 extra pancreatic glycemic normalization. The objective
of this article is to provide an overview of current evidence on the
potential therapeutic benefits of gliptins to combat Sars-Cov-2
infection.